Revolution Medicines Inc Ordinary Shares RVMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
-
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
-
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
-
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)
Trading Information
- Previous Close Price
- $44.86
- Day Range
- $43.70–45.56
- 52-Week Range
- $15.44–48.61
- Bid/Ask
- $44.01 / $44.71
- Market Cap
- $7.33 Bil
- Volume/Avg
- 3,482 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8,581.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 443
- Website
- https://www.revmed.com
Comparables
Valuation
|
Metric
|
RVMD
|
ACLX
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.49 | 9.26 | 2.68 |
Price/Sales | 8,581.49 | 29.59 | 221.87 |
Price/Cash Flow | — | 545.32 | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVMD
|
ACLX
|
CLDX
|
|---|---|---|---|
Quick Ratio | 15.10 | 5.85 | 29.06 |
Current Ratio | 15.42 | 6.01 | 29.36 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
RVMD
ACLX
CLDX
Profitability
|
Metric
|
RVMD
|
ACLX
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −28.36% | −1.88% | −19.66% |
Return on Equity (Normalized) | −32.03% | −3.31% | −20.83% |
Return on Invested Capital (Normalized) | −35.40% | −7.10% | −20.72% |
Return on Assets
RVMD
ACLX
CLDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xfmmjwlrhy | Jtf | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zcrhtvs | Fxjthzg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rrcxrghz | Knqgm | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xwdfvpwq | Qbjxcz | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Gvbgrghp | Cyp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Cthfdrmqd | Vzsf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Hsxhhvjvt | Qbvxx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Qykygqxx | Vtmj | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hqfytpqh | Mscxjpb | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mxwjlbrhk | Vklphc | $12.6 Bil |
United States